title: Open studies with prazosin in the treatment of essential hypertension. Prazosin Research Group in Japan.
abstract: The clinical usefulness of prazosin was investigated in 67 patients with mild to moderate essential hypertension for 6 to 12 weeks. The daily doses were increased from 3 to 9 mg according to the responses of the patients. The average reduction of mean arterial blood pressure by 6 weeks' prazosin treatment was 13-4 +/- 1-7 mm Hg. Thirty-three patients (49-3%) showed good or excellent responses to prazosin. Serious side effects or laboratory abnormalities did not appear in this trial, through postural dizziness was found in 6-0%. Prazosin seems to be a useful antihypertensive agent in the treatment of patients with mild or moderate essential hypertension.
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D011799:Quinazolines; D011224:Prazosin